Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Norepinephrine Transporter Imaging in Addiction Disorders

This study is ongoing, but not recruiting participants.
National Institute on Alcohol Abuse and Alcoholism (NIAAA)
Information provided by (Responsible Party):
Marc Potenza, Yale University Identifier:
First received: October 29, 2012
Last updated: April 24, 2017
Last verified: April 2017
In this study we propose to study 24 unmedicated abstinent alcohol dependent patients, 24 obese individuals and 24 individually matched healthy control subjects and determine Norepinephrine Transporter (NET) expression in vivo using (S,S)-[11C]MRB and PET.

Condition Intervention
Alcohol Dependence
Drug: (S,S)-[11C]MRB

Study Type: Observational
Study Design: Observational Model: Case-Control
Time Perspective: Prospective
Official Title: Norepinephrine Transporter Imaging in Addiction Disorders

Resource links provided by NLM:

Further study details as provided by Yale University:

Estimated Enrollment: 72
Study Start Date: July 2007
Estimated Study Completion Date: July 2018
Primary Completion Date: July 2012 (Final data collection date for primary outcome measure)
Groups/Cohorts Assigned Interventions
Subjects diagnosed with alcohol dependence
Drug: (S,S)-[11C]MRB
PET radioligand
Subjects diagnosed with obesity
Drug: (S,S)-[11C]MRB
PET radioligand
Subjects deemed to be medically healthy
Drug: (S,S)-[11C]MRB
PET radioligand

Detailed Description:
In this study we propose to study 24 unmedicated abstinent alcohol dependent patients, 24 obese individuals and 24 individually matched healthy control subjects and determine NET expression in vivo using (S,S)-[11C]MRB and PET. This will provide novel insight into alterations in pre- and post-synaptic homeostasis in alcoholism and obese people with the goal to explain regulatory processes and their alterations in these disorders. A better understanding of brain mechanisms and contributory stress would have an enormous impact on the public's understanding of the vulnerabilities for these disorders, influence medical and legal response to these problems, could lead to a new understanding of these phenomena, and stimulate a better means of prevention and treatment.

Ages Eligible for Study:   18 Years to 50 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Sampling Method:   Probability Sample
Study Population
24 unmedicated abstinent alcohol dependent patients, 24 obese individuals and 24 individually matched healthy control subjects

Inclusion Criteria:

  1. age 18-50 years inclusive;
  2. able to read and write English;
  3. for women, being in follicular phase of menstrual cycle at the time of the PET scan as determined by calculating the time since the last menses and assessments of serum hormone levels;
  4. 30 < BMI < 35 for obese subjects (upper limit of 35 selected given our experience with heavier individuals fitting comfortably in the MRI scanner) and 18.5 < BMI <25 for normal weight subjects, and no recent weight changes in prior 12 weeks prior to the study;
  5. for alcohol dependent patients meet current DSM-IV criteria for alcohol dependence or being in partial remission; abstinence on the MRI and PET scan days will be determined by patient self-report, breath alcohol tests (BACs) conducted during inpatient stay at the CNRU/GCRC, participants have to be non-obese BMI < 30, and
  6. for current daily smokers, having smoked 10 or more cigarettes daily for the past year and CO level > 10 ppm at intake; for non-smokers, no tobacco consumption for more than one year and never having used tobacco daily.

Exclusion Criteria:

  1. any major neurological illness or injury and any current or prior clinically significant mental health or substance use disorder (with possible exception of nicotine dependence and alcohol dependence per the inclusion criteria) as determined by SCID interview and the judgement of the PI;
  2. use of any psychoactive medication within past three weeks;
  3. any significant unstable medical condition such as asthma or heart disease which may limit the interpretation of the imaging results, for example due to changes in tracer delivery in hypertensive patients;
  4. IQ<70 based on past intelligence testing;
  5. any metal in body that would pose a risk with MRI; and
  6. claustrophobia that would interfere with MRI or PET imaging;
  7. presence of alcohol and drug use in the 72 hours prior to scanning, with the exception of tobacco;
  8. pregnancy or nursing for women,
  9. peri- and post- menopausal women, and those with ovarectomies will be excluded
  10. current eating disorders, including binge eating.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01719458

United States, Connecticut
Yale University School of Medicine
New Haven, Connecticut, United States, 06510
Sponsors and Collaborators
Yale University
National Institute on Alcohol Abuse and Alcoholism (NIAAA)
Principal Investigator: Marc N Potenza, MD, PhD Yale University
  More Information

Responsible Party: Marc Potenza, Professor of Psychiatry, Child Study, and Neurobiology, Yale University Identifier: NCT01719458     History of Changes
Other Study ID Numbers: 0705002688
RL1AA017540 ( US NIH Grant/Contract Award Number )
Study First Received: October 29, 2012
Last Updated: April 24, 2017

Additional relevant MeSH terms:
Alcohol-Related Disorders
Substance-Related Disorders
Chemically-Induced Disorders
Mental Disorders
Adrenergic alpha-Agonists
Adrenergic Agonists
Adrenergic Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Physiological Effects of Drugs
Autonomic Agents
Peripheral Nervous System Agents
Vasoconstrictor Agents processed this record on May 23, 2017